Korea Centers for Disease Control and Prevention

Lg Chemical Ltd.

Ho Sun Son

Sang Won Lee

Sang Gu Yeo

Jin Ho Lee

Dong Myung Kim

Sun Hwa Lee

Jong Hyun Kim

Young Kwan Kim

Chang Yong Hong

June Woo Lee

Sang Woong Kim

Tae Sik Park

Kwi Sung Park

Seung Bin Cha

Eunice Eun Kyeong Kim

The attenuated vaccinia virus strain KVAC103 was obtained by subculturing a vaccinia virus strain 103 times in VERO cells. The attenuated vaccinia virus strain KVAC103 has significantly low toxicity, shows reduced skin lesions, and, at the same time, induces effectively immune responses to poxvirus. Thus, it can be used as a poxvirus vaccine while causing less side effects.

Attenuated vaccinia virus KVAC103 strain

Disclosed herein is a novel recombinant virus vector derived from the attenuated vaccinia virus strain KVAC103. The recombinant virus vector is obtained by inserting an exogenous gene into the KVAC103 and may be used as a safe vaccine delivery vehicle in mammals. Particularly, recombinant viruses obtained by rescuing some of the genes deleted from the parent virus have an enhanced ability to proliferate in cells being cultured, and thus are easily produced. In addition, the recombinant viruses express an increased level of an exogenous antigen, and thus has enhanced immunogenic efficacy. Such recombinant virus vectors may be used in vaccines for preventing diseases, therapeutic vaccines, and molecular biological studies.

Recombinant vaccinia virus derived from KVAC103 strain

The present invention relates to a novel flavone derivative, pharmaceutically acceptable salt, hydrate, solvate and isomer thereof which is useful as an inhibitor against Cyclin Dependent Kinase (CDK), a process for preparation thereof, and a composition of anti-cancer agent or agent for treating neurodegenerative disease comprising this compound as an active ingredient.

CDK inhibitors having flavone structure

Growing community of inventors

Daejeon, South Korea

Ho Sun Son